| __timestamp | Amicus Therapeutics, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 28427000 |
| Thursday, January 1, 2015 | 76943000 | 37065000 |
| Friday, January 1, 2016 | 104793000 | 41199000 |
| Sunday, January 1, 2017 | 149310000 | 43415000 |
| Monday, January 1, 2018 | 270902000 | 57564000 |
| Tuesday, January 1, 2019 | 286378000 | 68853000 |
| Wednesday, January 1, 2020 | 308443000 | 67229000 |
| Friday, January 1, 2021 | 272049000 | 60932000 |
| Saturday, January 1, 2022 | 276677000 | 74771000 |
| Sunday, January 1, 2023 | 152381000 | 73741000 |
In pursuit of knowledge
In the ever-evolving world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. has consistently outpaced Amphastar Pharmaceuticals, Inc. in R&D investment. From 2014 to 2023, Amicus Therapeutics increased its R&D spending by over 220%, peaking in 2020. In contrast, Amphastar Pharmaceuticals saw a more modest growth of approximately 160% during the same period.
Amicus Therapeutics' aggressive investment strategy underscores its dedication to pioneering new treatments, while Amphastar's steady increase reflects a more conservative approach. Notably, in 2023, Amicus Therapeutics' R&D expenses were nearly double those of Amphastar, highlighting its prioritization of innovation. This trend suggests that Amicus Therapeutics is positioning itself as a leader in pharmaceutical advancements, potentially offering groundbreaking therapies in the near future.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Pharming Group N.V. vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs Amicus Therapeutics, Inc.
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Soleno Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Iovance Biotherapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?